Investigator |
Title |
Sponsor |
ID |
Dates |
Amount |
Emily M Eshleman, PHD |
Epithelial antigen presentatio |
National Institutes of Health (NIH) |
F32AI147591 |
4/1/22-3/31/23 |
$1,272 |
Ian P Lewkowich |
Elucidating the mechanisim of |
National Institutes of Health (NIH)/University of Cincinnati |
011429-00080 |
4/1/21-3/31/22 |
$10,000 |
David A Hildeman, PHD |
Regulation of C. difficile colitis by host genetic |
National Institutes of Health (NIH)/University of Cincinnati |
013939-00002 |
9/17/21-8/31/22 |
$10,122 |
Senad Divanovic, PHD |
Fibrin(ogen) control of metabolic inflammation and |
National Institutes of Health (NIH)/University of North Carolina |
5116413 |
12/1/21-11/30/22 |
$14,531 |
David A Hildeman, PHD |
Obtain healthy reference tissu |
National Institutes of Health (NIH)/University of Cincinnati |
012507-002 |
9/1/19-6/30/21 |
$20,165 |
Harry Leighton Grimes, PHD |
Defining human hematopoietic cells via transcriptomes an |
National Institutes of Health (NIH) |
1R21HL150678-01 |
1/1/21-12/31/21 |
$26,649 |
Harry Leighton Grimes, PHD |
Mechanisms whereby IFN-gamma sensitizes AML to the |
National Institutes of Health (NIH)/University of Pittsburgh |
AWD00003978 |
4/20/21-3/31/22 |
$35,168 |
Theresa Alenghat |
Microbiota-sensitive epigenetic regulation of IBD |
Kenneth Rainin Foundation |
KRF_Alenghat |
4/1/22-3/31/23 |
$50,000 |
Michael B Jordan, MD |
Harnessing insights from immun |
Cancer Free Kids |
CFK_Jordan |
7/1/21-6/30/22 |
$50,000 |
Maria Eugenia Fields, PHD |
Pathogenic potential of Th17 a |
American Diabetes Association |
ADA Fields - Divanov |
7/1/21-6/30/22 |
$65,645 |
Senad Divanovic, PHD |
Immunopathogenesis of non-alcoholic fatty liver di |
National Institutes of Health (NIH) |
R01DK099222 |
8/1/21-7/31/22 |
$67,836 |
Claire A Chougnet, PHD |
Mechanistic and therapeutic ro |
National Institutes of Health (NIH)/University of California-Davis |
cfda 93.847 |
6/1/20-5/31/21 |
$70,720 |
Theresa Alenghat |
Dietary regulation of innate intestinal immunity |
Burroughs Wellcome Foundation/University of Cincinnati |
BWF_Alenghat |
7/1/21-6/30/22 |
$100,000 |
Claire A Chougnet, PHD |
Discovery of Molecular Targets |
National Institutes of Health (NIH)/UCLA School of Public Health |
R01HD098389 |
4/1/21-3/31/22 |
$103,488 |
Andrew Herr, PHD |
Rapid, safe suppression of IgE |
National Institutes of Health (NIH)/University of Cincinnati |
012329-003 |
7/1/21-6/30/22 |
$112,783 |
Andrew Herr, PHD |
Mechanisms of staphylococcal skin colonization - Resubmi |
National Institutes of Health (NIH)/University of Nebraska Medical Center |
34-5301-2207-201 |
9/15/21-8/31/22 |
$206,972 |
Michael B Jordan, MD |
Redefining hemophagocytic lymphohistiocytosis in h |
National Institutes of Health (NIH) |
R21CA256390 |
12/1/21-11/30/22 |
$218,538 |
Chandrashekhar Pasare DVM |
(PQ10) Role of Gut Microbiota |
National Institutes of Health (NIH)/The University of Texas Southwestern |
PO: 000001910A GMO 2 |
9/1/21-8/31/22 |
$221,363 |
Artem Barski, PHD |
An experimentally-refined, dyn |
National Institutes of Health (NIH) |
RAI153442B |
3/1/22-2/28/23 |
$351,914 |
Harry Leighton Grimes, PHD |
Regulation of functionally discrete hematopietic s |
National Institutes of Health (NIH) |
R01DK121062 |
1/1/22-12/31/22 |
$260,848 |
David A Hildeman, PHD |
Proteasome targeting for alloreactive plasma cells |
National Institutes of Health (NIH)/University of Pennsylvania |
580121 |
7/1/21-6/30/22 |
$310,102 |
Claire A Chougnet, PHD |
Regulation and function of immune suppressive T ce |
National Institutes of Health (NIH) |
1R56AG065327-01A1 |
9/1/21-8/31/22 |
$325,950 |
Andrew Herr, PHD |
Studies of Metal-Dependent Intercellular Adhesion in Staphylococcal Biofilms |
National Institutes of Health (NIH) |
2R01GM094363-06A1 |
7/1/21-6/30/23 |
$339,112 |
Theresa Alenghat |
Epigenomic control of antimicrobial immunity in the intestine |
National Institutes of Health (NIH) |
R01DK114123 |
5/1/22-4/30/23 |
$357,887 |
Emily R Miraldi, PHD |
Dynamic regulatory network models of human respons |
National Institutes of Health (NIH)/Icahn School of Medicine at Mount Sinai |
0255-E053-4609 |
6/1/21-5/31/22 |
$398,294 |
Ian P Lewkowich |
Perinatal Dysbiosis, Lung Development and Asthma |
National Institutes of Health (NIH) |
R01HL149366 |
6/1/22-5/31/23 |
$398,560 |
Ian P Lewkowich |
Preconceptual paternal allergen exposure, offsprin |
National Institutes of Health (NIH) |
1R21AI156185-01A1 |
6/1/22-5/31/23 |
$437,250 |
Jonathan D Katz, PHD |
Manipulating DNA Damage-respon |
National Institutes of Health (NIH) |
R01DK117632 |
1/1/22-12/31/22 |
$446,790 |
Chandrashekhar Pasare DVM |
Innate mechanisms of regulatio |
National Institutes of Health (NIH) |
R01AI123176 |
1/4/22-12/31/22 |
$477,000 |
Senad Divanovic, PHD |
Immunopathogenesis of non-alcoholic fatty liver disease |
National Institutes of Health (NIH) |
R01DK099222 |
8/1/21-7/31/22 |
$554,436 |
Senad Divanovic, PHD |
Inflammatory vigor in heteroge |
Department of Defense Army |
W81XWH2010392 |
7/1/21-6/30/22 |
$577,143 |
Harry Leighton Grimes, PHD |
Modeling myelodysplasia |
National Institutes of Health (NIH) |
R01CA253981 |
1/1/22-12/31/22 |
$592,469 |
Tamara Tilburgs, PHD |
THE ROLE OF HLA-G /C EXTRAVILLOUS TROPHOBLASTS IN |
Burroughs Wellcome Foundation/University of Cincinnati |
FWA 00002988 |
6/1/21-3/31/22 |
$667,501 |
Claire A Chougnet, PHD |
Prenatal inflammatory exposures and neonatal immune deve |
National Institutes of Health (NIH) |
U01ES029234 |
9/1/21-8/31/22 |
$800,299 |
Michael B Jordan, MD |
Abatacept for the treatment of |
Food and Drug Administration |
1R01FD007267-01 |
9/10/21-6/30/22 |
$815,329 |
Chandrashekhar Pasare DVM |
Regulation of TLR signaling, Inflammation and Anti |
National Institutes of Health (NIH) |
1R01AI155426-01A1 |
7/1/21-6/30/22 |
$964,613 |
Total Annual Grant Award Dollars |
$10,460,749 |